Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pacira Pharm Inc 5401 WEST KENNEDY BOULEVARD SUITE 890 TAMPA FL 33609 USA

www.pacira.com P: 813-553-6680

Description:

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.

Key Statistics

Overview:

Market Capitalization, $K 1,350,389
Enterprise Value, $K 1,320,929
Shares Outstanding, K 46,501
Annual Sales, $ 674,980 K
Annual Net Income, $ 41,960 K
Last Quarter Sales, $ 181,240 K
Last Quarter Net Income, $ 24,870 K
EBIT, $ 144,960 K
EBITDA, $ 224,280 K
60-Month Beta 0.76
% of Insider Shareholders 6.60%
% of Institutional Shareholders 99.73%
Float, K 43,432
% Float 93.40%
Short Volume Ratio 0.59

Growth:

1-Year Return -26.79%
3-Year Return -58.25%
5-Year Return -26.45%
5-Year Revenue Growth 100.12%
5-Year Earnings Growth 620.69%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.89 on 02/29/24
Latest Earnings Date 05/01/24
Earnings Per Share ttm 2.16
EPS Growth vs. Prev Qtr 36.54%
EPS Growth vs. Prev Year 18.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PCRX Ratios

Ratio
Price/Earnings ttm 13.20
Price/Earnings forward 13.43
Price/Earnings to Growth N/A
Return-on-Equity % 12.81%
Return-on-Assets % 6.80%
Profit Margin % 6.22%
Debt/Equity 0.14
Price/Sales 1.96
Price/Cash Flow 7.38
Price/Book 1.56
Book Value/Share 18.74
Interest Coverage 4.04
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar